The research suggests that liraglutide, a drug originally developed for diabetes (Victoza) and weight management (Saxenda), may significantly reduce the frequency of debilitating migraine.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

For liraglutide specifically, which is currently sold in genericized versions due to patent expiration, Lexaria is now searching for a pharmaceutical partner interested in utilizing DehydraTECH to ...

Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes. JAMA Internal Medicine, 2016; 176 (7): 939 DOI: 10.1001/jamainternmed.2016.1540; ...

Study: One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.Image Credit: Pixel-Shot / Shutterstock.com. A recent JAMA Network Open study compares the weight loss ...

Although liraglutide activates GLP-1 receptors in the brain, the drug's weight loss effects are independent of GLP-1R activity in the hindbrain, area postrema, vagus nerve, and paraventricular ...

In that study, DehydraTECH-liraglutide outperformed the Rybelsus® control group by week 12 both in terms of blood sugar and body weight control, by 11.53% (p<0.0001) and 11.13% (p=0.0395 ...

We measured liraglutide in plasma and CSF with a radioimmunoassay specific for the N-terminus of the GLP-1 moiety of liraglutide. Mean plasma liraglutide was 31 (range: 21–63) nmol l−1.

Children who used the weight loss drug liraglutide in a late-stage trial lost significantly more weight than children who got a placebo, according to a new study. CNN values your feedback 1.

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy ...

Liraglutide, which is sold under the brand name Saxenda, helped children between the ages of 6 and under 12 reduce their body mass index (BMI) by 7.4 per cent in a 56-week trial.

Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical ...